Menu
Not yet recruiting NCT07399574

Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples

Observational Diquat Poisoning

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Portable Mass Spectrometry Analysis System for Quantitative Diquat Detection (with Diquat Quantitative Detection Kit; In-Situ/Ambient Ionization Mass Spectrometry Method).
Who it may be relevant to
Registry conditions: Diquat Poisoning. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Accuracy, Safety, and Clinical Performance of a Diquat Quantitative Detection Kit (In-Situ Ionization Mass Spectrometry) and a Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples (Whole Blood/Plasma)

Overview

This is an observational, non-interventional diagnostic accuracy study designed to evaluate a diquat quantitative detection kit (ambient ionization mass spectrometry method) and a portable mass spectrometry analysis system for measuring diquat concentrations in human blood samples (whole blood/plasma), using LC-MS/MS as the clinical gold standard for comparison.

Interventions

  • Device Portable Mass Spectrometry Analysis System for Quantitative Diquat Detection (with Diquat Quantitative Detection Kit; In-Situ/Ambient Ionization Mass Spectrometry Method)
    The portable mass spectrometry analysis system is an in vitro diagnostic device used with a diquat quantitative detection kit based on an in-situ/ambient ionization mass spectrometry method to quantify diquat concentrations in human blood samples. Whole blood specimens collected in routine clinical care will be analyzed using this device, and the quantitative results will be compared against those obtained using the reference standard method, liquid chromatography-tandem mass spectrometry (LC-MS

Primary outcome measures

  • Bland-Altman agreement [Time frame: Baseline]
  • Correlation coefficient between portable MS and LC-MS/MS [Time frame: Baseline]
  • Relative deviation at medical decision levels [Time frame: Baseline]
Secondary outcome measures (2)
  • Recovery rate (spiked mixed samples vs fresh samples) [Time frame: Baseline]
  • Precision (Coefficient of Variation, CV) [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Patients with suspected or clinically diagnosed acute diquat poisoning, providing whole blood and/or plasma samples, including qualified residual specimens retained after prior clinical testing when available.
  • The participant or their legally authorized representative can fully understand the study purpose and procedures, voluntarily agrees to participate, and is willing and able to comply with the study requirements.
  • Sample collection is performed according to routine clinical standards, with no apparent ethical concerns related to sample acquisition.

Exclusion criteria

  • Abnormal sample appearance, such as visible flocculent material or other gross abnormalities.
  • The participant is unable to provide a specimen, or the specimen does not meet testing requirements.
  • Any participant considered inappropriate for inclusion by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Nanjing Drum Tower Hospital — Nanjing

Identifiers

NCT: NCT07399574 · 2025-1207-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗